Research
Hormonal
Women with polycystic ovary syndrome (PCOS) exhibit a distinct dyslipidemic profile characterized by elevated triglycerides, elevated LDL cholesterol, and reduced HDL cholesterol compared to controls, independent of obesity status.
If you have PCOS, you need a complete lipid panel (including ApoA-I and Lipoprotein(a)) regardless of your weight. Lifestyle changes (diet/exercise) are the first-line treatment, but you may require statins if LDL remains high, as your hormonal profile drives atherogenic changes independent of body mass.
GoodSupportsHIGH confidence
In recent meta-analysis, triglycerides and low-density lipoprotein (LDL) cholesterol levels were 26 mg/dL and 12 mg/dL higher, and high-density lipoprotein cholesterol concentration was 6 mg/dL lower in women with PCOS than those of controls.
Why this rating
Supported by multiple meta-analyses and large cohort studies, though some qualitative LDL findings vary by population.
Source
Dyslipidemia in women with polycystic ovary syndrome
Jinju Kim et al. · Obstetrics & Gynecology Science · 2013
DOI 10.5468/ogs.2013.56.3.137
narrative_reviewCited 185×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification (diet and exercise) is the first-line therapy for dyslipidemia in PCOS, and statins are a novel therapeutic approach that improves lipid profiles and reduces testosterone and insulin resistance.Strong
- Women with PCOS have an increased proportion of atherogenic small dense LDL particles and elevated Lipoprotein(a), which are independent risk factors for cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →